The DOI matches its Crossref record.
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori: Review: non-bismuth quadruple therapy for H. pylori
Open accessAbstract
BACKGROUND: Traditional standard triple therapy for Helicobacter pylori infection (PPI-clarithromycin-amoxicillin) can easily be converted to non-bismuth quadruple (concomitant) therapy by the addition of a nitroimidazole twice daily. AIM: To critically review evidence on the role of non-bismuth quadruple therapy (PPI-clarithromycin-amoxicillin-nitroimidazole) in the treatment of H. pylori infection. METHODS: Bibliographical searches were performed in MEDLINE and relevant congresses. RESULTS: The first randomised comparison of the non-bismuth quadruple therapy and the sequential (PPI-amoxicillin 5days plus PPI-clarithromycin-nitroimidazole 5days) regimens recently concluded that both were similar in terms of efficacy and safety and that the sequential administration protocol may be unnecessarily complex. Several randomised controlled trials (and one meta-analysis) have demonstrated that non-bismuth quadruple therapy is more effective than and is equally well tolerated as standard triple therapy. A meta-analysis of 15 studies (1723 patients) revealed a mean H. pylori cure rate (intention-to-treat) of 90% for non-bismuth quadruple therapy. A tendency towards better results with longer treatments (7-10days vs. 3-5days) has been observed, so it seems reasonable to recommend the length of treatment by achieving maximal cure rates (10days). Clarithromycin resistance may reduce the efficacy of non-bismuth quadruple therapy, although the decrease in eradication rates seems to be far lower than in standard triple therapy. Experience with the non-bismuth quadruple therapy in patients with metronidazole-resistant strains is still very limited. CONCLUSIONS: Non-bismuth quadruple (concomitant) therapy appears to be an effective, safe, and well-tolerated alternative to triple therapy and is less complex than sequential therapy. Therefore, this regimen appears well suited for use in settings where the efficacy of triple therapy is unacceptably low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312288 · Cited by 2,946
Self-citationManagement of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F., Gensini, G. F., Gisbert, J. P., Graham, D. Y., Rokkas, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302084 · Cited by 2,266
Self-citationLanas, A., & Chan, F. K. L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32404-7 · Cited by 984
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Fallone, C. A., Chiba, N., van Zanten, S. V., Fischbach, L., Gisbert, J. P., Hunt, R. H., Jones, N. L., Render, C., Leontiadis, G. I., Moayyedi, P., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.006 · Cited by 927
Self-citationRational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence
Graham, D. Y., Lee, Y., & Wu, M. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.05.028 · Cited by 347
Metadata
- Authors
- Gisbert, J. P., & Calvet, X.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-07-11
- Volume
- 34
- Issue
- 6
- Pages
- 604-617
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W1920776299
- Cited by
- 180
- References
- 0
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori: Review: non-bismuth quadruple therapy for H. pylori. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04770.x
- The paper
- Gisbert, J. P., & Calvet, X. (2011). Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori: Review: non-bismuth quadruple therapy for H. pylori. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04770.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.